Europe’s pharma industry saw a rise of 18.5% in deal activity during June 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 32 pharma industry deals worth $86.95bn were announced for the region in June 2019, against the 12-month average of 27 deals.
Of all the deal types, venture financing saw most activity in June 2019 with 15 transactions, representing a 46.9% share for the region.
In second place was M&A with 12 deals, followed by private equity deals with five transactions, respectively capturing a 37.5% and 15.6% share of the overall deal activity for the month.
How well do you really know you competitors?
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In terms of value of deals, M&A was the leading category in Europe’s pharma industry with $86.67bn, while venture financing and private equity deals totalled $205.06m and $73.29m, respectively.
Europe pharma industry deals in June 2019: Top deals
The top five pharma deals accounted for 99.8% of the overall value during June 2019.
The combined value of the top five pharma deals stood at $86.73bn, against the overall value of $86.95bn recorded for the month. The top announced pharma deal tracked by GlobalData in June 2019 was AbbVie’s $85.74bn acquisition of Allergan.
In second place was the $519.43m asset transaction with NovImmune by Swedish Orphan Biovitrum and in third place was Karo Pharma‘s $360.71m acquisition of Trimb Healthcare.
The $62.85m venture financing of Laboratoris Sanifit by Alta Life Sciences, Caixa Capital Risc, SGEIC, Columbus Venture Partners SGEIC, Andera Partners, Forbion Capital Partners Management Services, Gilde Healthcare Partners, HealthEquity, SCR, The Lundbeck Foundation and Ysios Capital Partners and Nazca Capital S.G.E.C.R.’s private equity deal with Diater Laboratories for $50.65m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.